Pipeline/Programs

We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline.

TRN

Candidate & Indication

Discovery

IND-enabling

Phase 1

Phase 2

Phase 3

HOX/MEIS

HOX/
MEIS

Lanraplenib
(SYK Inhibitor)

Target #1
(PPI Modulator)

AR

Target #2 Modulator
(Cofactor Modulator)

Additional programs from mapping and screening the MYC, AR, MYB, IRF4 and other TRNs

*IND filed

We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.